2021 ESC/EACTS Guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the …
A Vahanian, F Beyersdorf, F Praz… - European heart …, 2022 - academic.oup.com
Health professionals are encouraged to take the ESC/EACTS Guidelines fully into account
when exercising their clinical judgment, as well as in the determination and the …
when exercising their clinical judgment, as well as in the determination and the …
2021 ESC/EACTS Guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the …
F Beyersdorf, A Vahanian, M Milojevic… - European journal of …, 2021 - academic.oup.com
731 F. Beyersdorf and A. Vahanian et al./European Journal of Cardio-Thoracic Surgery
guidelines, which is freely available via the ESC and EACTS website and hosted on the EHJ …
guidelines, which is freely available via the ESC and EACTS website and hosted on the EHJ …
Valve-in-valve transcatheter aortic valve replacement versus redo surgical aortic valve replacement: an updated meta-analysis
MPBO Sá, J Van den Eynde, M Simonato… - Cardiovascular …, 2021 - jacc.org
Objectives The aim of this study was to evaluate early results of valve-in-valve (ViV)
transcatheter aortic valve replacement (TAVR) versus redo surgical aortic valve replacement …
transcatheter aortic valve replacement (TAVR) versus redo surgical aortic valve replacement …
5-year follow-up from the PARTNER 2 aortic valve-in-valve registry for degenerated aortic surgical bioprostheses
Objectives The aim of this study was to report the outcomes of valve-in-valve (ViV)
transcatheter aortic valve replacement (TAVR) at 5 years. Background TAVR for …
transcatheter aortic valve replacement (TAVR) at 5 years. Background TAVR for …
Valvular heart disease: from mechanisms to management
F Praz, F Beyersdorf, K Haugaa, B Prendergast - The Lancet, 2024 - thelancet.com
Valvular heart disease is common and its prevalence is rapidly increasing worldwide.
Effective medical therapies are insufficient and treatment was historically limited to the …
Effective medical therapies are insufficient and treatment was historically limited to the …
Late outcomes of valve-in-valve transcatheter aortic valve implantation versus re-replacement: Meta-analysis of reconstructed time-to-event data
Aims To evaluate all-cause mortality in ViV-TAVI versus redo SAVR in patients with failed
bioprostheses. Methods Study-level meta-analysis of reconstructed time-to-event data from …
bioprostheses. Methods Study-level meta-analysis of reconstructed time-to-event data from …
[HTML][HTML] Valve-in-valve transcatheter aortic valve implantation versus repeat surgical aortic valve replacement in patients with a failed aortic bioprosthesis
Background Limited data are available regarding clinical outcomes of valve-in-valve (ViV)
transcatheter aortic valve implantation (TAVI) following the United States Food and Drug …
transcatheter aortic valve implantation (TAVI) following the United States Food and Drug …
Long-Term Outcomes of Valve-in-Valve Transcatheter Aortic Valve Implantation Versus Redo Surgical Aortic Valve Replacement: Meta-Analysis of Kaplan–Meier …
MP Sá, X Jacquemyn, D Serna-Gallegos… - The American Journal of …, 2024 - Elsevier
Valve-in-valve (ViV) transcatheter aortic valve implantation (ViV-TAVI) in patients with failed
bioprostheses arose as an alternative to redo surgical aortic valve replacement (SAVR). To …
bioprostheses arose as an alternative to redo surgical aortic valve replacement (SAVR). To …
Valve‐in‐Valve Transcatheter Aortic Valve Replacement Versus Redo Surgical Aortic Valve Replacement for Failed Surgical Aortic Bioprostheses: A Systematic …
M Raschpichler, S de Waha, D Holzhey… - Journal of the …, 2022 - Am Heart Assoc
Background In the absence of randomized controlled trials, reports from nonrandomized
studies comparing valve‐in‐valve implantation (ViV) to redo surgical aortic valve …
studies comparing valve‐in‐valve implantation (ViV) to redo surgical aortic valve …
Lifetime management of aortic valve disease: Aligning surgical and transcatheter armamentarium to set the tone for the present and the future
MP Sá, B Ramlawi, S Sicouri… - Journal of Cardiac …, 2022 - Wiley Online Library
Transcatheter aortic valve replacement (TAVR) has already received the green light for high‐
, intermediate‐and low‐risk profiles and is an alternative for all patients regardless of age. It …
, intermediate‐and low‐risk profiles and is an alternative for all patients regardless of age. It …